HTA23 Reasons for a Negative Pharmaceutical Benefits Advisory Committee (PBAC) Review in Rare Diseases in Australia: A Comprehensive Analysis
Year: 2023
Type: conference-abstract
Abstract: The Pharmaceutical Benefits Advisory Committee (PBAC) plays a crucial role in evaluating the clinical and cost-effectiveness of medications for reimbursement in Australia. However, the process for rare diseases can pose unique challenges. The objective of this study was to identify and analyse the reasons for negative PBAC reviews in rare diseases, focusing on the objectives, methods, results, and conclusions of the assessment process.
Source: Value in Health
Authors: A. Mumford, O. Darlington, S.J. Lyttle, A. Shaw
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: hybrid
Estimated APC paid: $3,200
OpenAlex ID: W4390128641